The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors

Urologic Clinics of North America

Volumn 39, Issue 2, 2012, Pages 133-148

  Shuch, Brian ^a   Singer, Eric A ^a   Bratslavsky, Gennady ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Bilateral kidney cancer; Hereditary kidney cancer; Multifocal kidney cancer; Renal cell carcinoma

Indexed keywords

AUTOSOMAL DOMINANT DISORDER; BILATERAL MULTIFOCAL ONCOCYTOMA; BILATERAL RENAL CANCER; BIRT HOGG DUBE SYNDROME; CANCER GENETICS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CRYOABLATION; EN BLOC HILAR DISSECTION; ENUCLEATION; ENZYME DEFICIENCY; FAMILIAL CANCER; FAMILIAL RENAL ONCOCYTOMA; FAMILY HISTORY; FASCIA; FOLLOW UP; GENE; GENETIC COUNSELING; GENETIC SCREENING; GEROTA CAPSULE; HEMOSTASIS; HEREDITARY LEIOMYOMATOSIS; HEREDITARY PAPILLARY RENAL CELL CARCINOMA; HEREDITARY RENAL CANCER; HISTOPATHOLOGY; HUMAN; IPSILATERAL RENAL CANCER; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY SURGERY; LAPAROSCOPIC SURGERY; LEIOMYOMATOSIS; MET GENE; METASTASIS POTENTIAL; MINIMALLY INVASIVE SURGERY; MULTIFOCALITY RENAL CANCER; NEPHRECTOMY; NEPHRON SPARING SURGERY; ONCOCYTOMA; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PATIENT CARE PLANNING; PENETRANCE; PEROPERATIVE ECHOGRAPHY; PHENOTYPE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RENOGRAPHY; RETROPERITONEAL FLANK APPROACH; REVIEW; SUCCINATE DEHYDROGENASE B DEFICIENCY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS 1; TUBEROUS SCLEROSIS 2; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LAPAROSCOPY; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REOPERATION; RISK ASSESSMENT; SURGICAL PROCEDURES, MINIMALLY INVASIVE; SURVIVAL ANALYSIS;

EID: 84859505442     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.01.006     Document Type: Review

References (114)

1. Cooperberg M.R., Mallin K., Kane C.J., et al. Treatment trends for stage I renal cell carcinoma. J Urol 2011, 186(2):394-399.
2. Campbell S.C., Novick A.C., Belldegrun A., et al. Guideline for management of the clinical T1 renal mass. J Urol 2009, 182(4):1271-1279.
3. Bratslavsky G., Linehan W.M. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 2010, 7(5):267-275.
4. Klatte T., Wunderlich H., Patard J.J., et al. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int 2007, 100(1):21-25.
5. Wunderlich H., Schlichter A., Zermann D., et al. Multifocality in renal cell carcinoma: a bilateral event?. Urol Int 1999, 63(3):160-163.
6. Blute M.L., Itano N.B., Cheville J.C., et al. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 2003, 169(4):1276-1281.
7. Klatte T., Patard J.J., Wunderlich H., et al. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 2007, 177(6):2081-2086. [discussion: 2086-7].
8. Rabbani F., Herr H.W., Almahmeed T., et al. Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 2002, 20(9):2370-2375.
9. Lau W.K., Blute M.L., Weaver A.L., et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000, 75(12):1236-1242.
10. Whang M., O'Toole K., Bixon R., et al. The incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol 1995, 154(3):968-970. [discussion: 970-1].
11. Schlichter A., Schubert R., Werner W., et al. How accurate is diagnostic imaging in determination of size and multifocality of renal cell carcinoma as a prerequisite for nephron-sparing surgery?. Urol Int 2000, 64(4):192-197.
12. Nissenkorn I., Bernheim J. Multicentricity in renal cell carcinoma. J Urol 1995, 153(3 Pt 1):620-622.
13. Minervini A., Serni S., Giubilei G., et al. Multiple ipsilateral renal tumors: retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy. Eur J Surg Oncol 2009, 35(5):521-526.
14. Rabbani F., McLoughlin M.G. Parameters predictive of multicentricity in renal cell carcinoma. Can J Urol 1997, 4(3):406-411.
15. Cheng W.S., Farrow G.M., Zincke H. The incidence of multicentricity in renal cell carcinoma. J Urol 1991, 146(5):1221-1223.
16. Mukamel E., Konichezky M., Engelstein D., et al. Incidental small renal tumors accompanying clinically overt renal cell carcinoma. J Urol 1988, 140(1):22-24.
17. Kletscher B.A., Qian J., Bostwick D.G., et al. Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol 1995, 153(3 Pt 2):904-906.
18. Gudbjartsson T., Jonasdottir T.J., Thoroddsen A., et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 2002, 100(4):476-479.
19. Purdue M.P., Johansson M., Zelenika D., et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 2011, 43(1):60-65.
20. Wu X., Scelo G., Purdue M.P., et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 2012, 21(2):456-462.
21. Hosoe S., Brauch H., Latif F., et al. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 1990, 8(4):634-640.
22. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260(5112):1317-1320.
23. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7(1):85-90.
24. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 2003, 361(9374):2059-2067.
25. Choyke P.L., Filling-Katz M.R., Shawker T.H., et al. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology 1990, 174(3 Pt 1):815-820.
26. Birt A.R., Hogg G.R., Dube W.J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 1977, 113(12):1674-1677.
27. Roth J.S., Rabinowitz A.D., Benson M., et al. Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 1993, 29(6):1055-1056.
28. Toro J.R., Glenn G., Duray P., et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999, 135(10):1195-1202.
29. Schmidt L.S., Warren M.B., Nickerson M.L., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001, 69(4):876-882.
30. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002, 2(2):157-164.
31. Schmidt L.S., Nickerson M.L., Warren M.B., et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 2005, 76(6):1023-1033.
32. Pavlovich C.P., Walther M.M., Eyler R.A., et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002, 26(12):1542-1552.
33. Pavlovich C.P., Grubb R.L., Hurley K., et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 2005, 173(5):1482-1486.
34. Kloepfer H.W., Krafchuk J., Derbes V., et al. Hereditary multiple leiomyoma of the skin. Am J Hum Genet 1958, 10(1):48-52.
35. Reed W.B., Walker R., Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973, 53(5):409-416.
36. Launonen V., Vierimaa O., Kiuru M., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001, 98(6):3387-3392.
37. Merino M.J., Torres-Cabala C., Pinto P., et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007, 31(10):1578-1585.
38. Alam N.A., Bevan S., Churchman M., et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001, 68(5):1264-1269.
39. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30(4):406-410.
40. Kiuru M., Launonen V., Hietala M., et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am J Pathol 2001, 159(3):825-829.
41. Vanharanta S., Pollard P.J., Lehtonen H.J., et al. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet 2006, 15(1):97-103.
42. Grubb R.L., Franks M.E., Toro J., et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007, 177(6):2074-2079. [discussion: 2079-80].
43. Zbar B., Tory K., Merino M., et al. Hereditary papillary renal cell carcinoma. J Urol 1994, 151(3):561-566.
44. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16(1):68-73.
45. Zhuang Z., Park W.S., Pack S., et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998, 20(1):66-69.
46. Choueri TK, Vaishampayan UN, Rosenberg JE, et al. A Phase II and biomarker study (MET111644) of the dual MET/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: final efficacy, safety, and PD results. 2012, ASCO GU Cancer Symposium. San Francisco (CA) [abstract 355].
47. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69(1):49-54.
48. Neumann H.P., Pawlu C., Peczkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004, 292(8):943-951.
49. Ricketts C., Woodward E.R., Killick P., et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008, 100(17):1260-1262.
50. Gill A.J., Pachter N.S., Chou A., et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 2011, 35(10):1578-1585.
51. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75(7):1305-1315.
52. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277(5327):805-808.
53. Clarke A., Hancock E., Kingswood C., et al. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 1999, 14(4):988-991.
54. Bjornsson J., Short M.P., Kwiatkowski D.J., et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996, 149(4):1201-1208.
55. Duffy K., Al-Saleem T., Karbowniczek M., et al. Mutational analysis of the von Hippel Lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients. Mod Pathol 2002, 15(3):205-210.
56. Dechet C.B., Bostwick D.G., Blute M.L., et al. Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol 1999, 162(1):40-42.
57. Perez-Ordonez B., Hamed G., Campbell S., et al. Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol 1997, 21(8):871-883.
58. Boris R.S., Benhammou J., Merino M., et al. The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma. J Urol 2011, 185(6):2050-2055.
59. Patel A.R., Lee B.H., Campbell S.C., et al. Bilateral synchronous sporadic renal tumors: pathologic concordance and clinical implications. Urology 2011, 78(5):1095-1099.
60. Tickoo S.K., Reuter V.E., Amin M.B., et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol 1999, 23(9):1094-1101.
61. Farkas L.M., Szekely J.G., Karatson A. Bilateral, multifocal renal oncocytomatosis with rapid progression leading to renal insufficiency. Nephrol Dial Transplant 1999, 14(9):2262-2263.
62. Adamy A., Lowrance W.T., Yee D.S., et al. Renal oncocytosis: management and clinical outcomes. J Urol 2011, 185(3):795-801.
63. Weirich G., Glenn G., Junker K., et al. Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 1998, 160(2):335-340.
64. Black J., Rotellar C., Rakowski T.A., et al. Bilateral nephrectomy and dialysis as an option for patients with bilateral renal cancer. Nephron 1988, 49(2):150-153.
65. Calne R.Y. Treatment of bilateral hypernephromas by nephrectomy, excision of tumour, and autotransplantation. Report of three cases. Lancet 1973, 2(7839):1164-1167.
66. Clark J.E. Transplantation for bilateral renal tumors. JAMA 1970, 211(8):1379.
67. Jochimsen P.R., Braunstein P.M., Najarian J.S. Renal allotransplantation for bilateral renal tumors. JAMA 1969, 210(9):1721-1724.
68. Fetner C.D., Barilla D.E., Scott T., et al. Bilateral renal cell carcinoma in von Hippel-Lindau syndrome: treatment with staged bilateral nephrectomy and hemodialysis. J Urol 1977, 117(4):534-536.
69. Mullin E.M., White R.D., Peterson L.J., et al. Bilateral renal carcinoma in von Hippel-Lindau disease. Urology 1976, 8(5):475-478.
70. Goldfarb D.A., Neumann H.P., Penn I., et al. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 1997, 64(12):1726-1729.
71. U S Renal Data System (USRDS). USRDS 2010 Annual data report. Minneapolis (MN): USRDS; 2010.
72. Stiles K.P., Moffatt M.J., Agodoa L.Y., et al. Renal cell carcinoma as a cause of end-stage renal disease in the United States: patient characteristics and survival. Kidney Int 2003, 64(1):247-253.
73. Ajithkumar T.V., Parkinson C.A., Butler A., et al. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007, 8(10):921-932.
74. Kasiske B.L., Cangro C.B., Hariharan S., et al. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2001, (Suppl 2):1-95. American Society of Transplantation.
75. Fadahunsi A.T., Sanford T., Linehan W.M., et al. Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit. J Urol 2011, 185(1):49-53.
76. Russo P. Open partial nephrectomy: an essential operation with an expanding role. Curr Opin Urol 2007, 17(5):309-315.
77. Singer E.A., Bratslavsky G. Management of locally recurrent kidney cancer. Curr Urol Rep 2010, 11(1):15-21.
78. Duffey B.G., Choyke P.L., Glenn G., et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol 2004, 172(1):63-65.
79. Walther M.M., Choyke P.L., Glenn G., et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999, 161(5):1475-1479.
80. Sutherland S.E., Resnick M.I., Maclennan G.T., et al. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter?. J Urol 2002, 167(1):61-64.
81. Carini M., Minervini A., Masieri L., et al. Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 2006, 50(6):1263-1268. [discussion: 1269-71].
82. Carini M., Minervini A., Lapini A., et al. Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival. J Urol 2006, 175(6):2022-2026. [discussion: 2026].
83. Minervini A., Ficarra V., Rocco F., et al. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol 2011, 185(5):1604-1610.
84. Rini B.I. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009, 27(19):3225-3234.
85. Boris R., Proano M., Linehan W.M., et al. Initial experience with robot assisted partial nephrectomy for multiple renal masses. J Urol 2009, 182(4):1280-1286.
86. Flum A.S., Wolf J.S. Laparoscopic partial nephrectomy for multiple ipsilateral renal tumors using a tailored surgical approach. J Endourol 2010, 24(4):557-561.
87. Steinberg A.P., Kilciler M., Abreu S.C., et al. Laparoscopic nephron-sparing surgery for two or more ipsilateral renal tumors. Urology 2004, 64(2):255-258.
88. Boris RS, Gupta G, Linehan WM, et al. Feasibility and outcomes of laparoscopic renal intervention after prior open ipsilateral retroperitoneal surgery. In: Society of Urologic Oncology, Winter Meeting. Besthesda (MD), 2010.
89. Bratslavsky G., Liu J.J., Johnson A.D., et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 2008, 179(1):67-70.
90. Johnson A., Sudarshan S., Liu J., et al. Feasibility and outcomes of repeat partial nephrectomy. J Urol 2008, 180(1):89-93. [discussion: 93].
91. Sporer A., Seebode J.J. Study of renal blood supply and its implication in renal pelvic surgery. Urology 1981, 17(1):18-21.
92. Walther M.M., Choyke P.L., Hayes W., et al. Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery. J Urol 1994, 152(6 Pt 1):1984-1987.
93. Choyke P.L., Daryanani K. Intraoperative ultrasound of the kidney. Ultrasound Q 2001, 17(4):245-253.
94. Choyke P.L., Pavlovich C.P., Daryanani K.D., et al. Intraoperative ultrasound during renal parenchymal sparing surgery for hereditary renal cancers: a 10-year experience. J Urol 2001, 165(2):397-400.
95. Shuch B., Lam J.S., Belldegrun A.S. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 2006, 7(1):31-38.
96. Thompson R.H., Lane B.R., Lohse C.M., et al. Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol 2010, 58(3):331-336.
97. Thompson R.H., Lane B.R., Lohse C.M., et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol 2010, 58(3):340-345.
98. Lane B.R., Russo P., Uzzo R.G., et al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. J Urol 2011, 185(2):421-427.
99. Thompson R.H., Frank I., Lohse C.M., et al. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol 2007, 177(2):471-476.
100. Walther M.M., Thompson N., Linehan W. Enucleation procedures in patients with multiple hereditary renal tumors. World J Urol 1995, 13(4):248-250.
101. Singer E.A., Bratslavsky G., Middelton L., et al. Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep 2011, 12(1):47-55.
102. Tsivian M., Moreira D.M., Caso J.R., et al. Predicting occult multifocality of renal cell carcinoma. Eur Urol 2010, 58(1):118-126.
103. Ansari M.S., Gupta N.P., Kumar P. von Hippel-Lindau disease with bilateral multiple renal cell carcinoma managed by right radical nephrectomy and left repeat partial nephrectomy. Int Urol Nephrol 2003, 35(4):471-473.
104. Novick A.C., Streem S.B. Long-term follow-up after nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J Urol 1992, 147(6):1488-1490.
105. Steinbach F., Novick A.C., Zincke H., et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995, 153(6):1812-1816.
106. Kunkle D.A., Uzzo R.G. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008, 113(10):2671-2680.
107. Park B.K., Kim C.K. Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results. J Urol 2010, 183(5):1703-1707.
108. Park S.Y., Park B.K., Kim C.K., et al. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel-Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery. Acta Radiol 2011, 52(6):680-685.
109. Shingleton W.B., Sewell P.E. Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease. J Urol 2002, 167(3):1268-1270.
110. Yang B., Autorino R., Remer E.M., et al. Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: the Cleveland Clinic experience with 3 years follow-up. Urol Oncol 2011, [Epub ahead of print].
111. Kowalczyk K.J., Hooper H.B., Linehan W.M., et al. Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol 2009, 182(5):2158-2163.
112. Singer E.A., Vourganti S., Lin K., et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of follow-up: the NCI experience. J Urol 2011, 185(Suppl 4):e746.
113. Herring J.C., Enquist E.G., Chernoff A., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001, 165(3):777-781.
114. Liu N.W., Khurana K., Sudarshan S., et al. Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes. J Urol 2010, 183(5):1719-1724.